Associations between the incidence of Fuchs' endothelial corneal dystrophy and menopausal hormone therapy use and exposure to endogenous estrogen
Maturitas · 2025-01 · 191 · 108132
DOI: 10.1016/j.maturitas.2024.108132 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Maturitas, 2025-01. Verfasst von Amy E Millen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of N…. Hauptthemen laut MEDLINE: Fuchs' Endothelial Dystrophy, Estrogens, Estrogen Replacement Therapy, Postmenopause. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, WHI NIH HHS, NEI NIH HHS.
Abstract (Originalsprache)
OBJECTIVES: End-stage Fuchs' endothelial corneal dystrophy is a leading cause of corneal blindness, with a higher prevalence in females than in males. Few modifiable risk factors have been identified. We examined associations between menopausal hormone therapy use (never/past/current), duration of hormone therapy use, estimated lifetime exposure to endogenous estrogen, and serum estradiol with incident Fuchs' endothelial corneal dystrophy in a cohort of postmenopausal women. STUDY DESIGN: This was a prospective analysis in the Women's Health Initiative Observational Study. MAIN OUTCOME MEASURES: Incident cases of Fuchs' endothelial corneal dystrophy were identified from the Women's Health Initiative Observational Study baseline (1993-1998) through 2019 using Medicare claims data. RESULTS: In 22,980 women, 1382 incident cases of Fuchs' endothelial corneal dystrophy (annualized incidence rate and 95 % confidence interval = 5.0 [4.8-5.3] cases per 1000 person-years) were identified. The adjusted hazard ratios and 95 % confidence intervals for Fuchs' endothelial corneal dystrophy were 1.02 (0.88-1.18) and 0.89 (0.79-0.997) for past and current hormone therapy use (vs. never use) at baseline, respectively. Adjusted hazard ratios (95 % confidence interval) were 0.90 (0.79-1.03) and 0.95 (0.84-1.08), p-trend = 0.36, for ≤10 and > 10 years, respectively, of hormone therapy use compared with no use; and the adjusted hazard ratio (95 % confidence interval) was 1.01 (0.88-1.15), p-trend = 0.87, for 46.7-59.0 versus 13.8-41.0 years of estimated lifetime exposure to endogenous estrogen. No statistically significant associations were observed with serum estradiol concentrations in a subset of participants. CONCLUSIONS: In this cohort of postmenopausal women, current hormone therapy use (vs. never use) showed evidence of protection against the development of Fuchs' endothelial corneal dystrophy; however, duration of hormone therapy use, estimated lifetime exposure to endogenous estrogen, or serum estradiol concentrations were not significantly associated with a decreased risk of Fuchs' endothelial corneal dystrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: aemillen@buffalo.edu.
- Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: jingnie@buffalo.edu.
- Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: yihuayue@buffalo.edu.
- Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA. Electronic address: chrisaa@umich.edu.
- Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: jww@buffalo.edu.
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA. Electronic address: robert-wallace@uiowa.edu.
Förderung
- NHLBI NIH HHS
- WHI NIH HHS
- NEI NIH HHS
- National Eye Institute
- National Institutes of Health
- National Heart Lung and Blood Institute
- US Department of Veterans Affairs
- US Department of Health and Human Services
Zitieren
APA
Millen, A. E., Nie, J., Yue, Y., Andrews, C. A., Wactawski-Wende, J., Wallace, R. B., Shadyab, A. H., & Patel, S. P. (2025). Associations between the incidence of Fuchs' endothelial corneal dystrophy and menopausal hormone therapy use and exposure to endogenous estrogen. Maturitas, 191, 108132. https://doi.org/10.1016/j.maturitas.2024.108132
Vancouver
Millen AE, Nie J, Yue Y, Andrews CA, Wactawski-Wende J, Wallace RB, et al. Associations between the incidence of Fuchs' endothelial corneal dystrophy and menopausal hormone therapy use and exposure to endogenous estrogen. Maturitas. 2025;191:108132. doi:10.1016/j.maturitas.2024.108132
BibTeX
@article{Millen2025,
author = {Millen, Amy E and Nie, Jing and Yue, Yihua and Andrews, Chris A and Wactawski-Wende, Jean and Wallace, Robert B and Shadyab, Aladdin H and Patel, Sangita P},
title = {Associations between the incidence of Fuchs' endothelial corneal dystrophy and menopausal hormone therapy use and exposure to endogenous estrogen},
journal = {Maturitas},
year = {2025},
volume = {191},
pages = {108132},
doi = {10.1016/j.maturitas.2024.108132}
}
EUVIMED